» Articles » PMID: 34899679

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases

Overview
Journal Front Immunol
Date 2021 Dec 13
PMID 34899679
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi-organ involvement. This entity has displaced viral hepatitis as the main cause of severe forms of hepatic diseases, although the onset and transition of MAFLD stages still remains unclear. Nevertheless, innate and adaptive immune responses seem to play an essential role in the establishment and further progression of this disease. The immune system is responsible of safeguard and preserves organs and systems function, and might be altered under different stimuli. Thus, the liver suffers from metabolic and immune changes leading to different injuries and loss of function. It has been stablished that cell-cell crosstalk is a key process in the hepatic homeostasis maintenance. There is mounting evidence suggesting that MAFLD pathogenesis is determined by a complex interaction of environmental, genetic and host factors that leads to a full plethora of outcomes. Therefore, herein we will revisit and discuss the interplay between immune mechanisms and MAFLD, highlighting the potential role of immunological markers in an attempt to clarify its relationship.

Citing Articles

Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications.

Guo Z, Wu Q, Xie P, Wang J, Lv W Front Immunol. 2024; 15:1336493.

PMID: 38352880 PMC: 10861763. DOI: 10.3389/fimmu.2024.1336493.


Obese visceral fat tissue inflammation: from protective to detrimental?.

Kolb H BMC Med. 2022; 20(1):494.

PMID: 36575472 PMC: 9795790. DOI: 10.1186/s12916-022-02672-y.


Emerging pharmacological treatment options for MAFLD.

Rojas A, Lara-Romero C, Munoz-Hernandez R, Gato S, Ampuero J, Romero-Gomez M Ther Adv Endocrinol Metab. 2022; 13:20420188221142452.

PMID: 36533188 PMC: 9747889. DOI: 10.1177/20420188221142452.


The protective roles of augmenter of liver regeneration in hepatocytes in the non-alcoholic fatty liver disease.

Dong Y, Zhang Y, Feng Y, An W Front Pharmacol. 2022; 13:928606.

PMID: 36304168 PMC: 9592723. DOI: 10.3389/fphar.2022.928606.


Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Yang K, Chen J, Zhang T, Yuan X, Ge A, Wang S Front Immunol. 2022; 13:949746.

PMID: 36159792 PMC: 9500378. DOI: 10.3389/fimmu.2022.949746.


References
1.
Munoz-Durango N, Arrese M, Hernandez A, Jara E, Kalergis A, Cabrera D . A Mineralocorticoid Receptor Deficiency in Myeloid Cells Reduces Liver Steatosis by Impairing Activation of CD8 T Cells in a Nonalcoholic Steatohepatitis Mouse Model. Front Immunol. 2021; 11:563434. PMC: 7772468. DOI: 10.3389/fimmu.2020.563434. View

2.
Orci L, Kreutzfeldt M, Goossens N, Rubbia-Brandt L, Slits F, Hammad K . Tolerogenic properties of liver macrophages in non-alcoholic steatohepatitis. Liver Int. 2019; 40(3):609-621. DOI: 10.1111/liv.14336. View

3.
Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

4.
Simon T, van der Sloot K, Chin S, Joshi A, Lochhead P, Ananthakrishnan A . IRGM Gene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease. Inflamm Bowel Dis. 2018; 24(10):2247-2257. PMC: 6230523. DOI: 10.1093/ibd/izy128. View

5.
Gomez-Hurtado I, Gallego-Duran R, Zapater P, Ampuero J, Aller R, Crespo J . Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. Liver Int. 2020; 40(9):2182-2193. DOI: 10.1111/liv.14571. View